Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Company has appointed Dato’ Seri Dr Chen Chaw Min as the Independent Non-Executive Chairman of the Board of Directors. The appointment is effective 15 July 2022, following the resignation of Tan Sri Ahmad bin Mohd Don on 12 July 2022.
Dato’ Seri Dr Chen, who was appointed to the Board on 3 August 2021, was with the Malaysian civil service from 1988 until his retirement in February 2021. He was the Secretary-General of the Ministry of Health (MOH) from July 2015 until his retirement and has also served in various capacities in the Ministry of Finance (MOF) from 1990 until 2014.
Dato’ Seri Dr. Chen said, “I feel privileged to take on this role at such an exciting time for Malaysian Genomics. The Group is currently expanding downstream to healthcare services and pioneering holistic care which will benefit many for the years to come, I hope that my experience in both MOH and MOF will be able to add knowledge and insights to support the Company’s growth.”
Dato’ Alvin Joseph, Executive Director of Malaysian Genomics said, “We welcome Dato’ Seri Chen to the Board of Malaysian Genomics as Chairman of the Board and look forward to working with him in ensuring proper governance in our business operations. His extensive experience in the civil service and in particular in MOH will be invaluable to us.”
“We would like to extend our thanks to Tan Sri Ahmad bin Mohd Don for his invaluable contributions and guidance to the Board in executing their duties. We wish him all the best in his future endeavours.”
Dato’ Seri Dr Chen obtained a doctorate in finance from Universiti Putra Malaysia in 2005. He received an MBA (Finance) from University of Illinois in 1997 and a Bachelor in Surveying from University of Technology, Malaysia, in 1985.
Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that it is uplifted from being classified as an affected listed corporation effective 13 June 2022. This followed the decision by Bursa Securities Malaysia Berhad to grant the Group a waiver in submitting a regularisation plan after being classified as an affected listed corporation pursuant to Rule 8.03A of the Listing Requirements. Bursa Securities had made the classification according to Rule 8.03A on 24 December 2019 and Malaysian Genomics had submitted an application seeking approval to exempt the Group from submitting a proposed regularisation plan on 24 March 2022. The waiver was granted on 10 June 2022.
Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “I am extremely thankful to the team for working diligently to get Malaysian Genomics out of the affected issuer classification status and welcome this news from the regulator. Our diversification into biopharmaceutical services, in particular the distribution of immunotherapy and cell therapies, has supported the financial performance of the Group. I believe that we can grow together, as a team.”
In a recent announcement on its 3Q 2022 performance, Malaysian Genomics reported a profit before tax (PBT) of RM1.96 million compared with PBT of RM0.2 million in 3Q 2021. Earnings per share (EPS) stood at 1.60 sen for 3Q 2022 compared with EPS of 0.19 sen in the corresponding quarter of the previous financial year.
Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, “We will continue to seek opportunities through collaborations and partnerships targeting new consumer and market segments, including those beyond Malaysia, as we strive to widen our reach and capitalise on heightened awareness on health issues across the region and farther afield. We look forward to introducing new products and markets in the near future.”
Dato’ Alvin Nesakumar, Executive Director of MGRC, said, “As we have shared before, we are also moving towards offering our products and services through adopting a business-to-consumer strategy to complement our business-to-business approach because trends are changing and technology enables us to reach out directly to consumers. This new approach will give us better insight into what the market needs.”
Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/ Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK]
Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to support Yayasan Seri Negara’s (YSN) Ihya Ramadhan 2022 programme through a monetary donation to help those in need.
Dato’ Seri Mazlan Lazim, Patron of Yayasan Seri Negara and Encik Azri Azerai, Executive Director of Malaysian Genomics Resource Centre [L-R]
The Ihya Ramadhan 2022 programme will be held in several locations throughout the country and involves the breaking of fast and the giving of monetary aid to orphans and the underprivileged.
Encik Azri Azerai, Executive Director of Malaysian Genomics, said, “We are happy and honoured to be able to assist YSN in their Ihya Ramadhan 2022 programme. Every little bit helps, and we want to do our part in easing the burden of those in need such as orphans and the underprivileged.”
Malaysian Genomics’ cash aid will be distributed to orphans and the underprivileged at the Shah Alam district police headquarters during the Ihya Ramadhan 2022 programme held at the location on 27 April 2022 at 6pm.
Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/ Malaysian Genomics Resource Centre Berhad: 0155 / [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK]
Malaysian Genomics Resource Centre Berhad (“Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research (“IMR”), the biomedical research arm of the Ministry of Health (“MOH”). Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.
Dato’ Alvin Nesakumar, Executive Director of Malaysian Genomics Resource Centre Berhad
Dato’ Alvin Nesakumar, Executive Director of Malaysian Genomics, said, “We are pleased to support IMR and MOH in this important effort to monitor the evolution of the COVID-19 virus, its variants and sub-variants. With our expertise and knowledge in genomics and bioinformatics, we can help IMR track and trace the virus for any variants of concern that the Government needs to be informed of as well as prepare for.”
Malaysian Genomics, whose cell laboratory is the only privately-owned BioSafety Level 2 (“BSL-2”) facility in Malaysia with the Current Good Manufacturing Practice (“cGMP”) certification, is moving towards becoming a premier healthcare provider through the production of CAR T-cells for cancer immunotherapy for solid cancers, as well as other cell engineering services. BSL-2 and cGMP certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells.
The Group is also ISO 9001:2015, ISO 15189:2014 and ISO 17025:2017 certified under the Integrated Management System.
Malaysian Genomics Resource Centre Berhad: http://www.mgrc.com.my/
